Exploring ROS Proto-Oncogen 1 (ROS-1), a receptor tyrosine kinase expression in cervical cancer: A clinicopathological analysis
Keywords:
Cervical cancer, ROS1 expression, immunohistochemistryAbstract
Background : Cervical cancer remains a leading cause of cancer-related mortality among women, with persistent HPV infection as the primary risk factor. Despite advancements in prevention and treatment, diagnosis often occurs at later stages. The exploration of biomarkers in cervical cancer may offer valuable insights into disease progression and potential therapeutic targets. However, the role of biomarkers like ROS1 remains inadequately studied, warranting further investigation to better understand its therapeutic potential.
Methods : This observational cross-sectional study involved 66 cervical cancer patients with a mean age of 47.14 ± 8.58 years. ROS1 expression was assessed using immunohistochemistry (IHC) on biopsy samples. Clinicopathological data, including cancer stage, histology, differentiation grade, and lymphovascular space invasion (LVSI), were collected. Statistical analysis was performed using the Chi-Square test and Mann-Whitney test to evaluate correlation between ROS1 expression and clinical factors.
Results : ROS1 positivity was observed in 56.1% of patients. Significant associations were found between ROS1 expression and parity (p = 0.040), clinical stage (p = 0.028), and histological subtype (p = 0.007). Higher expression was notably linked to advanced stages and adenocarcinoma cases. Mann-Whitney analysis revealed a significant difference in ROS1 expression between squamous and non-squamous histologies (p = 0.0007).
Conclusion : ROS1 expression is significantly correlated with disease progression in cervical cancer, particularly in adenocarcinoma subtypes. These findings suggest that ROS1 could serve as a valuable prognostic biomarker and a potential target for precision therapies in cervical cancer. Further studies are warranted to validate this and explore one as a therapeutic target.
References
1 Aga SS, Yasmeen N, Khan MA. Cervical cancer and its screening: assessing the knowledge, awareness, and perception among health and allied students. Educ Res Int. 2022. doi: 10.1155/2022/4608643
2 Andayani N, Handoko B, Murtaza. The role of ROS1 mutation in non-small cell lung cancer. J Int Surg Clin Med. 2022;2(1):10–17. doi: 10.51559/jiscm.v2i1.15
3 Ten Berge DMHJ, et al. Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands. Lung Cancer. 2023;181:107253. doi: 10.1016/j.lungcan.2023.107253
4 Bhatla N, et al. Cancer of the cervix uteri: 2021 update. Int J Gynecol Obstet. 2021;155(S1):28–44. doi: 10.1002/ijgo.13865
5 Brambs CE, et al. The prognostic impact of grading in FIGO IB and IIB squamous cell cervical carcinomas. Geburtshilfe Frauenheilkunde. 2019;79(2):198–204. doi: 10.1055/a-0828-7681
6 Choi S, Ismail A, Pappas-Gogos G. HPV and cervical cancer: a review of epidemiology and screening uptake in the UK. Pathogens. 2023;12:298
7 Cohen PA, et al. Cervical cancer. Lancet. 2019;393(10167):169–182. doi: 10.1016/S0140-6736(18)32470-X
8 D’Angelo A, et al. Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms, and the newer generation of targeted therapies. Cancers. 2020;12(11):1–18. doi: 10.3390/cancers12113293
9 Dabi Y, et al. Identification of a low-risk population for parametrial invasion in patients with early-stage cervical cancer. J Transl Med. 2018;16(1):1–9. doi: 10.1186/s12967-018-1531-6
10 Drilon A, et al. ROS1-dependent cancers — biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18(1):35–55. doi: 10.1038/s41571-020-0408-9
11 Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):1–13. doi: 10.1186/s12943-018-0782-4
12 Dyrbekk APH, et al. Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer. Diagn Pathol. 2023;18(70):1–13. doi: 10.1186/s13000-023-01357-1
13 Fowler JR, et al. Cervical cancer. StatPearls Publishing LLC; 2023.
14 Gendarme S, et al. ROS-1 fusions in non-small-cell lung cancer: evidence to date. Curr Oncol. 2022;29(2):641–658.
15 Gil-Ibañez B, et al. Tumor size and oncological outcomes in patients with early cervical cancer treated by fertility preservation surgery: A multicenter retrospective cohort study. Cancers. 2022;14(9).
16 Guaitoli G, et al. Deepening the knowledge of ROS1 rearrangements in non-small cell lung cancer: diagnosis, treatment, resistance and concomitant alterations. Int J Mol Sci. 2021;22(23):1–17. doi: 10.3390/ijms222312867
17 Hiranuma K, et al. Rare FGFR fusion genes in cervical cancer and transcriptome-based subgrouping of patients with a poor prognosis. Cancer Med. 2023;12(17):17835–17848. doi: 10.1002/cam4.6415
18 Hull R, et al. Cervical cancer in low and middle-income countries (Review). Oncol Lett. 2020;20(3):2058–2074. doi: 10.3892/ol.2020.11754
19 Indonesia Cancer Care Community. Indonesia Cancer Care Community - ICCC. Available at: https://iccc.id/kanker-pada-anak [Accessed: 20 June 2021]
20 Iyer SR, et al. Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. EMBO Mol Med. 2023;15(10):1–20. doi: 10.15252/emmm.202217367
21 Kashyap N, et al. Assessment of sign and symptoms of cervical cancer amongst the patient: A case-control study. Asia Pac J Oncol Nurs. 2019;6(3):308–312. doi: 10.33698/nrf0226
22 Kementerian Kesehatan Republik Indonesia. Panduan Penatalaksanaan Kanker Serviks. Jakarta; 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Nur Hikmah Kusuma, Nugraha Utama Pelupessy, Lenny Maria Lisal, Rina Masadah, Sharvianty Arifuddin, Andi Alfiann Zainuddin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
